Last 47 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -26.06 | — | — | 75.44 | — | — | 1.16 | — | — | — | — | — | — | — | 14.11 | — | — | — | 28.04 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -49.7% | — | — | — | — | — | — | |
| P/S Ratio | 12.24 | 38.82 | 30.27 | 8.84 | 4.56 | 19.78 | 0.79 | 234.71 | — | — | — | 231.41 | 44.78 | 60.28 | 4.69 | 17.19 | 27.67 | 28.72 | 8.17 | 63.15 | 42.62 |
| — | +96.3% | +3735.9% | -96.2% | — | — | — | +1.4% | — | — | — | +1246.1% | +61.8% | +109.9% | -42.6% | -72.8% | -35.1% | -38.8% | -84.4% | -31.8% | -70.6% | |
| P/B Ratio | 15.45 | 25.08 | 14.91 | 16.60 | 9.30 | 4.23 | 2.50 | 41.86 | 12.37 | 9.52 | 7.12 | 18.92 | 10.04 | 9.99 | 5.91 | 10.85 | 8.35 | 7.85 | 10.98 | 18.60 | 15.96 |
| — | +493.4% | +495.4% | -60.3% | -24.8% | -55.6% | -64.8% | +121.2% | +23.2% | -4.7% | +20.5% | +74.4% | +20.2% | +27.2% | -46.2% | -41.7% | -47.7% | -60.2% | -29.0% | +7.2% | +66.6% | |
| P/FCF | — | — | 27.27 | 206.07 | 89.99 | — | 0.94 | — | — | — | — | — | — | — | — | — | — | — | 21.40 | — | — |
| — | — | +2794.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +219.1% | — | — | |
| EV / EBITDA | — | — | — | 50.07 | 23.87 | — | 1.46 | — | — | — | — | — | — | — | 13.25 | — | — | — | 27.76 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -52.3% | — | — | — | — | — | — | |
| EV / EBIT | 84.72 | — | — | 46.54 | 20.84 | — | 1.45 | — | — | — | — | — | — | — | 12.77 | — | — | — | 27.63 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | -53.8% | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | -20.1% | 76.0% | 79.3% | 98.2% | 95.7% | 91.6% | 92.0% | 98.3% | 90.6% | — |
| — | 0.0% | 0.0% | 0.0% | — | — | — | +598.7% | — | — | — | -121.0% | -17.0% | -13.8% | -0.1% | +5.6% | — | — | — | — | — | |
| Operating Margin | 11.9% | -226.0% | -191.6% | 15.5% | 17.2% | -596.2% | 70.2% | -6456.5% | — | — | — | -3845.3% | -673.0% | -649.0% | 32.9% | -67.4% | -265.5% | -224.9% | 27.4% | -230.8% | -169.5% |
| — | +62.1% | -372.7% | +100.2% | — | — | — | -67.9% | — | — | — | -5608.1% | -153.5% | -188.5% | +20.3% | +70.8% | -56.7% | -223.9% | +131.8% | -104.4% | +74.2% | |
| Net Margin | -0.2% | -258.2% | -180.0% | 11.7% | -9.3% | -631.1% | 68.3% | -6923.4% | — | — | — | -3741.6% | -681.4% | -650.5% | 33.3% | -66.1% | -270.8% | -222.3% | 29.2% | -229.1% | -165.5% |
| — | +59.1% | -363.7% | +100.2% | — | — | — | -85.0% | — | — | — | -5563.0% | -151.6% | -192.7% | +13.9% | +71.2% | -63.6% | -240.9% | +135.8% | -135.4% | +73.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -0.5% | -36.5% | -22.9% | 5.8% | -4.6% | -29.1% | 100.1% | -140.1% | -64.3% | -40.9% | -37.5% | -57.7% | -32.8% | -24.3% | 11.3% | -10.1% | -19.2% | -15.6% | 10.8% | -16.1% | -15.0% |
| — | -25.3% | -122.8% | +104.1% | +92.8% | +28.9% | +367.2% | -142.9% | -96.3% | -68.4% | -431.4% | -468.3% | -71.1% | -56.3% | +5.0% | +37.0% | -27.9% | -129.3% | +280.5% | -255.6% | -47.7% | |
| ROA | -0.1% | -8.9% | -6.9% | 2.1% | -1.7% | -11.9% | 28.6% | -16.1% | -16.9% | -18.6% | -15.8% | -19.1% | -14.0% | -12.2% | 5.5% | -5.2% | -11.8% | -9.9% | 6.6% | -9.3% | -8.8% |
| — | +25.2% | -123.9% | +112.8% | +89.8% | +36.1% | +280.7% | +15.8% | -20.0% | -52.2% | -390.2% | -265.8% | -18.6% | -23.3% | -17.4% | +44.0% | -35.1% | -146.8% | +254.8% | -129.7% | +2.4% | |
| ROIC | 9.3% | -8.3% | -8.6% | 4.6% | 3.8% | -10.6% | 27.1% | -13.3% | -14.6% | -17.7% | -14.8% | -19.2% | -17.7% | -19.9% | 10.5% | -9.5% | -15.6% | -13.5% | 8.9% | -17.1% | -25.3% |
| — | +21.3% | -131.9% | +134.8% | +125.9% | +40.2% | +282.3% | +30.5% | +17.3% | +11.2% | -241.6% | -102.8% | -13.6% | -47.2% | +17.4% | +44.6% | +38.4% | +34.2% | +191.2% | -219.3% | -113.2% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.73 | 1.85 | 2.29 | 0.56 | 0.73 | 1.37 | 1.08 | 15.55 | 4.46 | 1.34 | 0.81 | 2.26 | 1.34 | 0.22 | 0.18 | 0.21 | 0.20 | 0.17 | 0.06 | 0.07 | 0.06 |
| — | +35.1% | +111.9% | -96.4% | -83.7% | +2.4% | +34.1% | +588.7% | +233.9% | +518.5% | +353.5% | +989.8% | +584.9% | +26.6% | +214.3% | +205.0% | +212.1% | +209.5% | +6.0% | +48.0% | +36.5% | |
| Debt / EBITDA | 3.00 | — | — | 6.63 | 7.25 | — | 1.91 | — | — | — | — | — | — | — | 1.63 | — | — | — | 0.58 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | +180.7% | — | — | — | — | — | — | |
| Current Ratio | 4.86 | 5.90 | 6.23 | 3.38 | 4.86 | 4.87 | 5.15 | 6.09 | 6.74 | 4.65 | 8.31 | 3.73 | 3.98 | 6.69 | 6.60 | 4.11 | 2.71 | 3.37 | 3.01 | 2.47 | 2.62 |
| — | +21.2% | +21.1% | -44.5% | -27.9% | +4.6% | -38.1% | +63.0% | +69.5% | -30.5% | +26.0% | -9.2% | +46.8% | +98.5% | +119.3% | +66.6% | +3.3% | +25.3% | -14.3% | -80.9% | -66.9% | |
| Quick Ratio | 4.86 | 5.90 | 6.23 | 3.38 | 4.86 | 4.87 | 5.15 | 6.09 | 6.74 | 4.65 | 8.31 | 3.73 | 3.98 | 6.55 | 6.60 | 4.64 | 2.87 | 3.32 | 2.96 | 2.43 | 2.59 |
| — | +21.2% | +21.1% | -44.5% | -27.9% | +4.6% | -38.1% | +63.0% | +69.5% | -29.0% | +26.0% | -19.6% | +38.8% | +97.4% | +122.8% | +91.1% | +10.5% | +25.1% | -14.7% | -80.7% | -66.8% | |
| Interest Coverage | 1.58 | -6.28 | -4.77 | 2.26 | 2.67 | -6.35 | 18.08 | -7.09 | -10.80 | -33.15 | -16.53 | -24.84 | -19.71 | -19.04 | 10.43 | -13.67 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ARWR stock.
Arrowhead Pharmaceuticals, Inc.'s current P/E is -26.1x. The average P/E over the last 1 quarters is 75.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Arrowhead Pharmaceuticals, Inc.'s current operating margin is 11.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Arrowhead Pharmaceuticals, Inc.'s business trajectory between earnings reports.